GSK to Showcase Transformative Respiratory Research at ERS Congress 2024

GSK to Showcase Transformative Respiratory Research at ERS Congress 2024

(IN BRIEF) GSK will present significant research at the 2024 European Respiratory Society (ERS) Congress, including data from phase III trials of its new biologic, depemokimab, for severe asthma. The presentations highlight GSK’s commitment to advancing respiratory medicine, with a focus on achieving long-term clinical remission for conditions like asthma and COPD. The company will also share insights into the use of Nucala and Trelegy in managing these diseases, aiming to improve patient outcomes globally.

(PRESS RELEASE) LONDON, 3-Sep-2024 — /EuropaWire/ — GSK is set to reveal groundbreaking research at the 2024 European Respiratory Society (ERS) International Congress, highlighting its latest advancements in respiratory medicine. The company will present 56 abstracts, including pivotal data from the SWIFT-1 and SWIFT-2 phase III trials, showcasing the potential of its ultra-long-acting biologic, depemokimab, in treating severe asthma.

The presentations will underscore GSK’s commitment to transforming the treatment landscape for respiratory diseases such as asthma, COPD, and refractory chronic cough. The data aims to demonstrate how GSK’s innovative therapies, including biologics and inhaled medicines, are pushing the boundaries of care, with a focus on achieving long-term clinical remission for patients.

Notably, GSK will also share new insights into the role of Nucala in managing COPD and asthma, and explore the potential of Trelegy in stabilizing disease progression. These findings reinforce GSK’s strategy of using cutting-edge science to reduce the global burden of respiratory conditions and improve patient outcomes.

Key abstracts presented at ERS

Encouraging new data will be presented from GSK’s portfolio that could transform outcomes for patients living with respiratory disease.

About GSK in respiratory

GSK continues to build on decades of pioneering work to deliver more ambitious treatment goals, develop the next generation standard of care, and redefine the future of respiratory medicine for hundreds of millions of people with respiratory diseases. With an industry-leading respiratory portfolio and pipeline of vaccines, targeted biologics and inhaled medicines, we are focused on improving outcomes and the lives of people living with all types of asthma and COPD along with less understood refractory chronic cough or rarer conditions like systemic sclerosis with interstitial lung disease. GSK is harnessing the latest science and technology with the aim to modify underlying disease dysfunction and prevent disease progression.

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at gsk.com.

Cautionary statement regarding forward-looking statements

GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D “Risk factors” in GSK’s Annual Report on Form 20-F for 2023, and GSK’s Q2 Results for 2024.

Media Contact:

Tim Foley
Vice President, Global Corporate Media Relations
corporate.media@gsk.com
+44 (0)20 8047 5502

SOURCE: GlaxoSmithKline plc